Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation

Core Viewpoint - Merck is projected to potentially lose up to $630 million in revenue from Gardasil due to changes in the U.S. vaccination recommendations for HPV, which no longer include three doses in the childhood vaccine schedule [1] Revenue Impact - The loss of revenue is attributed to the U.S. no longer recommending three doses of the HPV vaccine in the childhood vaccination schedule, which is expected to significantly affect Merck's financial performance this year [1]